SI3288379T1 - Peptidne sestave in načini uporabe - Google Patents

Peptidne sestave in načini uporabe

Info

Publication number
SI3288379T1
SI3288379T1 SI201631458T SI201631458T SI3288379T1 SI 3288379 T1 SI3288379 T1 SI 3288379T1 SI 201631458 T SI201631458 T SI 201631458T SI 201631458 T SI201631458 T SI 201631458T SI 3288379 T1 SI3288379 T1 SI 3288379T1
Authority
SI
Slovenia
Prior art keywords
methods
peptide compositions
peptide
compositions
Prior art date
Application number
SI201631458T
Other languages
English (en)
Inventor
Cagri G. Besirli
Alexander J. Bridges
John K. Freshley
William A. Hunke
Linda L. Johnson
Francis X. Smith
Ethan Sylvain
David N. Zacks
Original Assignee
Onl Therapeutics, Inc.
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onl Therapeutics, Inc., The Regents Of The University Of Michigan filed Critical Onl Therapeutics, Inc.
Publication of SI3288379T1 publication Critical patent/SI3288379T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SI201631458T 2015-05-01 2016-04-29 Peptidne sestave in načini uporabe SI3288379T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
EP16789830.3A EP3288379B1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (1)

Publication Number Publication Date
SI3288379T1 true SI3288379T1 (sl) 2022-06-30

Family

ID=57217771

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631458T SI3288379T1 (sl) 2015-05-01 2016-04-29 Peptidne sestave in načini uporabe

Country Status (22)

Country Link
US (4) US10508134B2 (sl)
EP (2) EP3997981A1 (sl)
JP (2) JP6884755B2 (sl)
KR (2) KR20240046280A (sl)
CN (2) CN113651873A (sl)
AU (1) AU2016258837B2 (sl)
BR (1) BR112017023479A2 (sl)
CA (1) CA2984154A1 (sl)
CY (1) CY1124911T1 (sl)
DK (1) DK3288379T3 (sl)
EA (2) EA202090184A3 (sl)
ES (1) ES2906173T3 (sl)
HK (1) HK1251979A1 (sl)
HR (1) HRP20220138T1 (sl)
HU (1) HUE057883T2 (sl)
LT (1) LT3288379T (sl)
MX (1) MX2017014075A (sl)
PL (1) PL3288379T3 (sl)
PT (1) PT3288379T (sl)
RS (1) RS62866B1 (sl)
SI (1) SI3288379T1 (sl)
WO (1) WO2016178993A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3288379T (lt) * 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
JP2023507603A (ja) * 2019-12-18 2023-02-24 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
WO2024031022A2 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024031024A1 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
EP1730186A2 (en) * 2004-03-31 2006-12-13 Xencor, Inc. Bmp-7 variants with improved properties
AU2005249383A1 (en) 2004-04-23 2005-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cell death modulation via antagonists of FasL and Fas activation
ZA200709251B (en) * 2005-05-10 2009-08-26 Alcon Inc Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
NZ568694A (en) * 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
JP2009518308A (ja) * 2005-12-01 2009-05-07 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション アポトーシスを阻害するための化合物及び方法
CA2708549C (en) * 2007-12-21 2014-04-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
WO2010102052A2 (en) * 2009-03-03 2010-09-10 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
EA201171188A1 (ru) * 2009-03-30 2012-05-30 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида
IN2012DN00754A (sl) * 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
BR112013021494B1 (pt) 2011-02-22 2021-09-08 California Institute Of Technology Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo
MX351353B (es) * 2011-06-06 2017-10-11 Kineta One Llc Composiciones farmacéuticas basadas en shk y métodos para prepararlas y usarlas.
US9428550B2 (en) 2012-01-18 2016-08-30 Governing Council Of The University Of Toronto Peptides and methods and uses thereof for preventing retinal disorders
KR101514238B1 (ko) * 2012-06-21 2015-04-28 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드의 신규 용도
CA2890238A1 (en) * 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
EP3254106A4 (en) 2015-02-05 2018-10-03 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
LT3288379T (lt) * 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EP3481433B1 (en) 2016-07-05 2024-07-03 University of Massachusetts Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
EP3768301A4 (en) 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
US20210121534A1 (en) 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Also Published As

Publication number Publication date
PT3288379T (pt) 2022-02-08
DK3288379T3 (da) 2022-02-07
EA202090184A2 (ru) 2020-05-31
US20230287052A1 (en) 2023-09-14
EA202090184A3 (ru) 2020-07-31
EP3288379A4 (en) 2018-10-24
EP3288379A1 (en) 2018-03-07
US20200123201A1 (en) 2020-04-23
KR20170140383A (ko) 2017-12-20
CN107708416B (zh) 2021-06-29
US11597749B2 (en) 2023-03-07
AU2016258837A1 (en) 2017-11-09
JP2021120400A (ja) 2021-08-19
ES2906173T3 (es) 2022-04-13
JP2018514590A (ja) 2018-06-07
HUE057883T2 (hu) 2022-06-28
CN107708416A (zh) 2018-02-16
KR20240046280A (ko) 2024-04-08
CY1124911T1 (el) 2023-01-05
LT3288379T (lt) 2022-02-25
JP6884755B2 (ja) 2021-06-09
RS62866B1 (sr) 2022-02-28
HRP20220138T1 (hr) 2022-05-27
PL3288379T3 (pl) 2022-03-07
EA035293B1 (ru) 2020-05-26
US10508134B2 (en) 2019-12-17
AU2016258837B2 (en) 2020-12-03
BR112017023479A2 (pt) 2018-07-24
US10829518B2 (en) 2020-11-10
EP3288379B1 (en) 2021-11-03
CA2984154A1 (en) 2016-11-10
EP3997981A1 (en) 2022-05-18
EA201792399A1 (ru) 2018-05-31
MX2017014075A (es) 2018-07-06
KR102652804B1 (ko) 2024-04-01
US20210094985A1 (en) 2021-04-01
CN113651873A (zh) 2021-11-16
WO2016178993A1 (en) 2016-11-10
US20180291062A1 (en) 2018-10-11
HK1251979A1 (zh) 2019-05-10

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
HK1252870A1 (zh) Sirp多肽組合物和使用方法
GB2582100B (en) CAS12C Compositions and methods of use
IL251834A0 (en) Pharmaceutical compositions containing peptide variants and methods of using them
GB201801933D0 (en) Engineered crispr-CAS9 compositions and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
ZA201701909B (en) Trichoderma compositions and methods of use
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
HK1248531A1 (zh) 免疫調節組合物及其使用方法
HK1251979A1 (zh) 肽組合物和使用方法
IL284236A (en) Modifications and uses of conotoxin peptides
HK1254960A1 (zh) 冷沉澱物組合物及其製備方法
HK1252057A1 (zh) 新穎的使用方法和組合物
IL256843B (en) Cleaning products and methods of using them
HK1250345A1 (zh) 包含15-氧代-epa或15-氧代-dgla的組合物及其製備和使用方法
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
HK1243404A1 (zh) 色酰胺組合物和使用方法
HK1248527A1 (zh) 牙科組合物和使用方法
IL261794A (en) Preparations and methods for using them
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them